Seres Therapeutics, Inc. (MCRB) Downgraded by BidaskClub to Hold
Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Wednesday, July 5th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $16.17.
Seres Therapeutics (MCRB) traded down 0.82% during mid-day trading on Friday, hitting $13.35. The company’s stock had a trading volume of 25,390 shares. The firm’s 50-day moving average is $12.49 and its 200-day moving average is $10.66. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09. The company’s market cap is $540.84 million.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. The business had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. Analysts predict that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the last quarter. State Street Corp increased its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 16,671 shares during the last quarter. Citadel Advisors LLC increased its position in Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares during the last quarter. Highbridge Capital Management LLC increased its position in Seres Therapeutics by 104.0% in the first quarter. Highbridge Capital Management LLC now owns 30,843 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 15,726 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in Seres Therapeutics during the first quarter valued at about $613,000. 75.31% of the stock is currently owned by hedge funds and other institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.